Cellectar Biosciences, Inc. (CLRB)Healthcare | Biotechnology | Florham Park, United States | NasdaqCM
2.90 USD
-0.05
(-1.695%) ⇩
(April 21, 2026, 1:48 p.m.
EDT)
Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:25 a.m. EDT
Short-term bullish momentum driven by FDA breakthrough designation and capital raises despite negative earnings; long-term hold-low due to unreliability of positive cash flows and lack of dividend income. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.112025 |
| AutoETS | 0.160441 |
| AutoTheta | 0.176218 |
| MSTL | 0.184361 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 5.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.478 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.129 |
| Market Cap | 12,296,389 |
| Forward P/E | -0.94 |
| Beta | 0.40 |
| Website | https://www.cellectar.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.67222226 |
| Address1 | 100 Campus Drive |
| All Time High | 307,529,984.0 |
| All Time Low | 2.43 |
| Ask | 3.71 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 25,070 |
| Average Daily Volume3 Month | 37,942 |
| Average Volume | 37,942 |
| Average Volume10Days | 25,070 |
| Beta | 0.404 |
| Bid | 2.16 |
| Bid Size | 2 |
| Book Value | 1.891 |
| City | Florham Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.9 |
| Current Ratio | 2.956 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.0 |
| Day Low | 2.82 |
| Debt To Equity | 4.129 |
| Display Name | Cellectar Biosciences |
| Dividend Date | 1,531,785,600 |
| Earnings Call Timestamp End | 1,772,631,000 |
| Earnings Call Timestamp Start | 1,772,631,000 |
| Earnings Timestamp | 1,772,631,000 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | -22,766,248 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.071 |
| Enterprise Value | 1,624,734 |
| Eps Current Year | -4.195 |
| Eps Forward | -3.1 |
| Eps Trailing Twelve Months | -8.35 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0212 |
| Fifty Day Average Change | -0.121199846 |
| Fifty Day Average Change Percent | -0.04011646 |
| Fifty Two Week Change Percent | -67.22223 |
| Fifty Two Week High | 20.7 |
| Fifty Two Week High Change | -17.800001 |
| Fifty Two Week High Change Percent | -0.8599034 |
| Fifty Two Week Low | 2.43 |
| Fifty Two Week Low Change | 0.47000003 |
| Fifty Two Week Low Change Percent | 0.19341564 |
| Fifty Two Week Range | 2.43 - 20.7 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,131,633,000,000 |
| Float Shares | 4,084,135 |
| Forward Eps | -3.1 |
| Forward P E | -0.93548393 |
| Free Cashflow | -16,425,541 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03911 |
| Held Percent Institutions | 0.087019995 |
| Implied Shares Outstanding | 4,240,134 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,750,723,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. |
| Long Name | Cellectar Biosciences, Inc. |
| Market | us_market |
| Market Cap | 12,296,389 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_37613299 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -21,791,036 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,508,380 |
| Number Of Analyst Opinions | 3 |
| Open | 2.9 |
| Operating Cashflow | -23,118,216 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 608 441 8120 |
| Previous Close | 2.95 |
| Price Eps Current Year | -0.69129914 |
| Price Hint | 4 |
| Price To Book | 1.5335802 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.778 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.049999952 |
| Regular Market Change Percent | -1.6949136 |
| Regular Market Day High | 3.0 |
| Regular Market Day Low | 2.82 |
| Regular Market Day Range | 2.82 - 3.0 |
| Regular Market Open | 2.9 |
| Regular Market Previous Close | 2.95 |
| Regular Market Price | 2.9 |
| Regular Market Time | 1,776,793,691 |
| Regular Market Volume | 26,053 |
| Return On Assets | -0.71009004 |
| Return On Equity | -1.7027 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,240,129 |
| Shares Percent Shares Out | 0.014400001 |
| Shares Short | 61,202 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 89,881 |
| Short Name | Cellectar Biosciences, Inc. |
| Short Percent Of Float | 0.0145000005 |
| Short Ratio | 1.09 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CLRB |
| Target High Price | 76.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 33.33333 |
| Target Median Price | 14.0 |
| Total Cash | 13,196,033 |
| Total Cash Per Share | 3.112 |
| Total Debt | 409,586 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.8856 |
| Two Hundred Day Average Change | -0.9856 |
| Two Hundred Day Average Change Percent | -0.2536545 |
| Type Disp | Equity |
| Volume | 26,053 |
| Website | https://www.cellectar.com |
| Zip | 7,932 |